Bone metastasis has a significant influence on the prognosis of prostate cancer(PCa) patients. In this review, we discussed the current application of PCa bone metastasis diagnosis with single-photon emission computed tomography (SPECT) and positron emission tomography/computed tomography (PET/CT) computer-aided diagnosis(CAD) systems. A literature search identified articles concentrated on PCa bone metastasis and PET/CT or SPECT CAD systems using the PubMed database. We summarized the previous studies focused on CAD systems and manual quantitative markers calculation, and the coincidence rate was acceptable. We also analyzed the quantification methods, advantages, and disadvantages of CAD systems. CAD systems can detect abnormal lesions of PCa patients’ ^99mTc-MDP-SPECT, ¹⁸F-FDG-PET/CT, ¹⁸F-NaF-PET/CT, and ⁶⁸ Ga-PSMA PET/CT images automated or semi-automated. CAD systems can also calculate the quantitative markers, which can quantify PCa patients’ whole-body bone metastasis tumor burden accurately and quickly and give a standardized and objective result. SPECT and PET/CT CAD systems are potential tools to monitor and quantify bone metastasis lesions of PCa patients simply and accurately, the future clinical application of CAD systems in diagnosing PCa bone metastasis lesions is necessary and feasible.